NK-1 receptor antagonists are a class of drugs that block the neurokinin-1 (NK1) receptors, which are activated by the neurotransmitter substance P. Substance P plays a key role in the body's vomiting reflex, as well as in pain perception and stress responses. By inhibiting NK1 receptors, these drugs are primarily used to prevent and treat nausea and vomiting, particularly those caused by chemotherapy, radiation therapy, or surgery.
The global NK-1 Receptor Antagonists market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of NK-1 Receptor Antagonists include Merck, TerSera Therapeutics, Helsinn Healthcare, Heron Therapeutics, Sandoz, Glenmark, Torrent Pharmaceuticals, Steriscience, Mylan, Fresenius Kabi, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for NK-1 Receptor Antagonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NK-1 Receptor Antagonists.
The NK-1 Receptor Antagonists market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global NK-1 Receptor Antagonists market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NK-1 Receptor Antagonists manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Merck
TerSera Therapeutics
Helsinn Healthcare
Heron Therapeutics
Sandoz
Glenmark
Torrent Pharmaceuticals
Steriscience
Mylan
Fresenius Kabi
MSN
Teva
Eugia Pharma
Lupin
Dr. Reddy's Laboratories
Chia Tai Tianqing Pharmaceutical
Qilu Pharmaceutical
Beijing Sihuan Pharmaceutical
Yichang Humanwell Pharmaceutical
Hansoh Pharma
Segment by Type
Aprepitant
Rolapitant
Fosaprepitant
Netupitant
Maropitant
Other
Segment by Application
Chemotherapy-induced Nausea and Vomiting (CINV)
Postoperative Nausea and Vomiting (PONV)
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of NK-1 Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of NK-1 Receptor Antagonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 NK-1 Receptor Antagonists 麻豆原创 Overview
1.1 Product Definition
1.2 NK-1 Receptor Antagonists by Type
1.2.1 Global NK-1 Receptor Antagonists 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Aprepitant
1.2.3 Rolapitant
1.2.4 Fosaprepitant
1.2.5 Netupitant
1.2.6 Maropitant
1.2.7 Other
1.3 NK-1 Receptor Antagonists by Application
1.3.1 Global NK-1 Receptor Antagonists 麻豆原创 Value by Application (2024-2030)
1.3.2 Chemotherapy-induced Nausea and Vomiting (CINV)
1.3.3 Postoperative Nausea and Vomiting (PONV)
1.3.4 Other
1.4 Global NK-1 Receptor Antagonists 麻豆原创 Size Estimates and Forecasts
1.4.1 Global NK-1 Receptor Antagonists Revenue 2019-2030
1.4.2 Global NK-1 Receptor Antagonists Sales 2019-2030
1.4.3 Global NK-1 Receptor Antagonists 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 NK-1 Receptor Antagonists 麻豆原创 Competition by Manufacturers
2.1 Global NK-1 Receptor Antagonists Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global NK-1 Receptor Antagonists Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global NK-1 Receptor Antagonists Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of NK-1 Receptor Antagonists, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of NK-1 Receptor Antagonists, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of NK-1 Receptor Antagonists, Product Type & Application
2.7 Global Key Manufacturers of NK-1 Receptor Antagonists, Date of Enter into This Industry
2.8 Global NK-1 Receptor Antagonists 麻豆原创 Competitive Situation and Trends
2.8.1 Global NK-1 Receptor Antagonists 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest NK-1 Receptor Antagonists Players 麻豆原创 Share by Revenue
2.8.3 Global NK-1 Receptor Antagonists 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global NK-1 Receptor Antagonists 麻豆原创 Scenario by Region
3.1 Global NK-1 Receptor Antagonists 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global NK-1 Receptor Antagonists Sales by Region: 2019-2030
3.2.1 Global NK-1 Receptor Antagonists Sales by Region: 2019-2024
3.2.2 Global NK-1 Receptor Antagonists Sales by Region: 2025-2030
3.3 Global NK-1 Receptor Antagonists Revenue by Region: 2019-2030
3.3.1 Global NK-1 Receptor Antagonists Revenue by Region: 2019-2024
3.3.2 Global NK-1 Receptor Antagonists Revenue by Region: 2025-2030
3.4 North America NK-1 Receptor Antagonists 麻豆原创 Facts & Figures by Country
3.4.1 North America NK-1 Receptor Antagonists 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America NK-1 Receptor Antagonists Sales by Country (2019-2030)
3.4.3 North America NK-1 Receptor Antagonists Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe NK-1 Receptor Antagonists 麻豆原创 Facts & Figures by Country
3.5.1 Europe NK-1 Receptor Antagonists 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe NK-1 Receptor Antagonists Sales by Country (2019-2030)
3.5.3 Europe NK-1 Receptor Antagonists Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific NK-1 Receptor Antagonists 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific NK-1 Receptor Antagonists 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific NK-1 Receptor Antagonists Sales by Region (2019-2030)
3.6.3 Asia Pacific NK-1 Receptor Antagonists Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America NK-1 Receptor Antagonists 麻豆原创 Facts & Figures by Country
3.7.1 Latin America NK-1 Receptor Antagonists 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America NK-1 Receptor Antagonists Sales by Country (2019-2030)
3.7.3 Latin America NK-1 Receptor Antagonists Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa NK-1 Receptor Antagonists 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa NK-1 Receptor Antagonists 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa NK-1 Receptor Antagonists Sales by Country (2019-2030)
3.8.3 Middle East and Africa NK-1 Receptor Antagonists Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global NK-1 Receptor Antagonists Sales by Type (2019-2030)
4.1.1 Global NK-1 Receptor Antagonists Sales by Type (2019-2024)
4.1.2 Global NK-1 Receptor Antagonists Sales by Type (2025-2030)
4.1.3 Global NK-1 Receptor Antagonists Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global NK-1 Receptor Antagonists Revenue by Type (2019-2030)
4.2.1 Global NK-1 Receptor Antagonists Revenue by Type (2019-2024)
4.2.2 Global NK-1 Receptor Antagonists Revenue by Type (2025-2030)
4.2.3 Global NK-1 Receptor Antagonists Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global NK-1 Receptor Antagonists Price by Type (2019-2030)
5 Segment by Application
5.1 Global NK-1 Receptor Antagonists Sales by Application (2019-2030)
5.1.1 Global NK-1 Receptor Antagonists Sales by Application (2019-2024)
5.1.2 Global NK-1 Receptor Antagonists Sales by Application (2025-2030)
5.1.3 Global NK-1 Receptor Antagonists Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global NK-1 Receptor Antagonists Revenue by Application (2019-2030)
5.2.1 Global NK-1 Receptor Antagonists Revenue by Application (2019-2024)
5.2.2 Global NK-1 Receptor Antagonists Revenue by Application (2025-2030)
5.2.3 Global NK-1 Receptor Antagonists Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global NK-1 Receptor Antagonists Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Company Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck NK-1 Receptor Antagonists Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 TerSera Therapeutics
6.2.1 TerSera Therapeutics Company Information
6.2.2 TerSera Therapeutics Description and Business Overview
6.2.3 TerSera Therapeutics NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.2.4 TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolio
6.2.5 TerSera Therapeutics Recent Developments/Updates
6.3 Helsinn Healthcare
6.3.1 Helsinn Healthcare Company Information
6.3.2 Helsinn Healthcare Description and Business Overview
6.3.3 Helsinn Healthcare NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolio
6.3.5 Helsinn Healthcare Recent Developments/Updates
6.4 Heron Therapeutics
6.4.1 Heron Therapeutics Company Information
6.4.2 Heron Therapeutics Description and Business Overview
6.4.3 Heron Therapeutics NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Heron Therapeutics NK-1 Receptor Antagonists Product Portfolio
6.4.5 Heron Therapeutics Recent Developments/Updates
6.5 Sandoz
6.5.1 Sandoz Company Information
6.5.2 Sandoz Description and Business Overview
6.5.3 Sandoz NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sandoz NK-1 Receptor Antagonists Product Portfolio
6.5.5 Sandoz Recent Developments/Updates
6.6 Glenmark
6.6.1 Glenmark Company Information
6.6.2 Glenmark Description and Business Overview
6.6.3 Glenmark NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Glenmark NK-1 Receptor Antagonists Product Portfolio
6.6.5 Glenmark Recent Developments/Updates
6.7 Torrent Pharmaceuticals
6.7.1 Torrent Pharmaceuticals Company Information
6.7.2 Torrent Pharmaceuticals Description and Business Overview
6.7.3 Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolio
6.7.5 Torrent Pharmaceuticals Recent Developments/Updates
6.8 Steriscience
6.8.1 Steriscience Company Information
6.8.2 Steriscience Description and Business Overview
6.8.3 Steriscience NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Steriscience NK-1 Receptor Antagonists Product Portfolio
6.8.5 Steriscience Recent Developments/Updates
6.9 Mylan
6.9.1 Mylan Company Information
6.9.2 Mylan Description and Business Overview
6.9.3 Mylan NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Mylan NK-1 Receptor Antagonists Product Portfolio
6.9.5 Mylan Recent Developments/Updates
6.10 Fresenius Kabi
6.10.1 Fresenius Kabi Company Information
6.10.2 Fresenius Kabi Description and Business Overview
6.10.3 Fresenius Kabi NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Fresenius Kabi NK-1 Receptor Antagonists Product Portfolio
6.10.5 Fresenius Kabi Recent Developments/Updates
6.11 MSN
6.11.1 MSN Company Information
6.11.2 MSN Description and Business Overview
6.11.3 MSN NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.11.4 MSN NK-1 Receptor Antagonists Product Portfolio
6.11.5 MSN Recent Developments/Updates
6.12 Teva
6.12.1 Teva Company Information
6.12.2 Teva Description and Business Overview
6.12.3 Teva NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Teva NK-1 Receptor Antagonists Product Portfolio
6.12.5 Teva Recent Developments/Updates
6.13 Eugia Pharma
6.13.1 Eugia Pharma Company Information
6.13.2 Eugia Pharma Description and Business Overview
6.13.3 Eugia Pharma NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Eugia Pharma NK-1 Receptor Antagonists Product Portfolio
6.13.5 Eugia Pharma Recent Developments/Updates
6.14 Lupin
6.14.1 Lupin Company Information
6.14.2 Lupin Description and Business Overview
6.14.3 Lupin NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Lupin NK-1 Receptor Antagonists Product Portfolio
6.14.5 Lupin Recent Developments/Updates
6.15 Dr. Reddy's Laboratories
6.15.1 Dr. Reddy's Laboratories Company Information
6.15.2 Dr. Reddy's Laboratories Description and Business Overview
6.15.3 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolio
6.15.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.16 Chia Tai Tianqing Pharmaceutical
6.16.1 Chia Tai Tianqing Pharmaceutical Company Information
6.16.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview
6.16.3 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
6.16.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
6.17 Qilu Pharmaceutical
6.17.1 Qilu Pharmaceutical Company Information
6.17.2 Qilu Pharmaceutical Description and Business Overview
6.17.3 Qilu Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
6.17.5 Qilu Pharmaceutical Recent Developments/Updates
6.18 Beijing Sihuan Pharmaceutical
6.18.1 Beijing Sihuan Pharmaceutical Company Information
6.18.2 Beijing Sihuan Pharmaceutical Description and Business Overview
6.18.3 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
6.18.5 Beijing Sihuan Pharmaceutical Recent Developments/Updates
6.19 Yichang Humanwell Pharmaceutical
6.19.1 Yichang Humanwell Pharmaceutical Company Information
6.19.2 Yichang Humanwell Pharmaceutical Description and Business Overview
6.19.3 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
6.19.5 Yichang Humanwell Pharmaceutical Recent Developments/Updates
6.20 Hansoh Pharma
6.20.1 Hansoh Pharma Company Information
6.20.2 Hansoh Pharma Description and Business Overview
6.20.3 Hansoh Pharma NK-1 Receptor Antagonists Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Hansoh Pharma NK-1 Receptor Antagonists Product Portfolio
6.20.5 Hansoh Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 NK-1 Receptor Antagonists Industry Chain Analysis
7.2 NK-1 Receptor Antagonists Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 NK-1 Receptor Antagonists Production Mode & Process
7.4 NK-1 Receptor Antagonists Sales and 麻豆原创ing
7.4.1 NK-1 Receptor Antagonists Sales Channels
7.4.2 NK-1 Receptor Antagonists Distributors
7.5 NK-1 Receptor Antagonists Customers
8 NK-1 Receptor Antagonists 麻豆原创 Dynamics
8.1 NK-1 Receptor Antagonists Industry Trends
8.2 NK-1 Receptor Antagonists 麻豆原创 Drivers
8.3 NK-1 Receptor Antagonists 麻豆原创 Challenges
8.4 NK-1 Receptor Antagonists 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Merck
TerSera Therapeutics
Helsinn Healthcare
Heron Therapeutics
Sandoz
Glenmark
Torrent Pharmaceuticals
Steriscience
Mylan
Fresenius Kabi
MSN
Teva
Eugia Pharma
Lupin
Dr. Reddy's Laboratories
Chia Tai Tianqing Pharmaceutical
Qilu Pharmaceutical
Beijing Sihuan Pharmaceutical
Yichang Humanwell Pharmaceutical
Hansoh Pharma
听
听
*If Applicable.